ATAI Life Sciences N.V [ATAI] stock prices are down -4.72% to $1.21 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ATAI shares have lost -2.42% over the last week, with a monthly amount drifted -14.18%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
ATAI Life Sciences N.V [NASDAQ: ATAI] stock has seen the most recent analyst activity on November 18, 2024, when H.C. Wainwright reiterated its Buy rating and also revised its price target to $10 from $15. Previously, Maxim Group upgraded its rating to Buy on April 03, 2024, and kept the price target unchanged to $6. On November 01, 2022, Loop Capital initiated with a Buy rating and assigned a price target of $18 on the stock. Maxim Group started tracking the stock assigning a Buy rating and suggested a price target of $25 on November 30, 2021. ROTH Capital initiated its recommendation with a Buy and recommended $32 as its price target on November 11, 2021. H.C. Wainwright started tracking with a Buy rating for this stock on October 18, 2021, and assigned it a price target of $40. In a note dated September 01, 2021, Jefferies initiated an Buy rating and provided a target price of $27 on this stock.
The stock price of ATAI Life Sciences N.V [ATAI] has been fluctuating between $1.03 and $2.64 over the past year. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. ATAI Life Sciences N.V [NASDAQ: ATAI] shares were valued at $1.21 at the most recent close of the market. An investor can expect a potential return of 395.87% based on the average ATAI price forecast.
Analyzing the ATAI fundamentals
The ATAI Life Sciences N.V [NASDAQ:ATAI] reported sales of 0.33M for trailing twelve months, representing a drop of -54.02%. Gross Profit Margin for this corporation currently stands at 0.46% with Operating Profit Margin at -333.06%, Pretax Profit Margin comes in at -482.72%, and Net Profit Margin reading is -484.64%. To continue investigating profitability, this company’s Return on Assets is posted at -0.94, Equity is -0.92 and Total Capital is -0.76. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.21.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.1400 points at the first support level, and at 1.0700 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.3300, and for the 2nd resistance point, it is at 1.4500.
Ratios To Look Out For
It’s worth pointing out that ATAI Life Sciences N.V [NASDAQ:ATAI]’s Current Ratio is 5.81. As well, the Quick Ratio is 5.81, while the Cash Ratio is 0.7. Considering the valuation of this stock, the price to sales ratio is 727.13, the price to book ratio is 1.39.
Transactions by insiders
Recent insider trading involved Kirpekar Sahil, Chief Business Officer, that happened on Mar 21 ’25 when 48563.0 shares were sold. Chief Medical Officer, Craig Kevin James completed a deal on Mar 21 ’25 to sell 11563.0 shares. Meanwhile, Rao Srinivas sold 75418.0 shares on Mar 21 ’25.
